Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
FOLFIRI + regorafenib
- Development stage
- Unknown
- Lead developer
- Bayer
- Modality
- Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Recombinant Proteins and Enzymes, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules, Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, Fragment-Derived Small Molecules → Multivalent & Scaffold-Based Small Molecules → Small Molecules
- Administration
- Intravenous, Oral
01
Overview
FOLFIRI + regorafenib is a combination therapy used primarily in the treatment of metastatic colorectal cancer, especially in patients who have progressed after standard first-line therapies. FOLFIRI is a chemotherapy regimen consisting of folinic acid (leucovorin), fluorouracil (5-FU), and irinotecan. Folinic acid enhances the effectiveness of 5-FU, which acts as an antimetabolite to disrupt DNA synthesis, while irinotecan inhibits topoisomerase I, blocking DNA replication and leading to cancer cell death[6][8][10]. Regorafenib is an oral multikinase inhibitor that targets multiple protein kinases involved in tumor angiogenesis, oncogenesis, and the tumor microenvironment. It inhibits kinases such as VEGFR1-3, PDGFR-β, FGFR1/2/3/4, KIT, RET, RAF-1/BRAF (including mutant BRAF), TIE2 and others[4][7]. The combination aims to leverage both cytotoxic chemotherapy and targeted inhibition of key signaling pathways for improved disease control. Clinical studies suggest this regimen can provide modest improvements in progression-free survival compared to FOLFIRI alone but may be associated with increased toxicity[3][4][5].
- Brand names
- Stivarga
- Other names
- regorafenib plus FOLFIRIregorafenib + folinic acid + fluorouracil + irinotecan
02
Targets
TS (Thymidylate synthase)KIT (c-KIT proto-oncogene receptor tyrosine kinase)VEGFR2 (Vascular endothelial growth factor receptor 2)BRAF (B-Raf proto-oncogene, serine/threonine kinase)PDGFRB (Platelet-derived growth factor receptor beta)TOP1 (DNA Topoisomerase I)RAF1 (c-Raf-1 (Y340D/Y341D))TEK (Tie2)VEGFR-1 (Vascular endothelial growth factor receptor 1)VEGFR3 (Vascular endothelial growth factor receptor 3)FGFR2 (Keratinocyte growth factor receptor)FGFR1 (Fibroblast growth factor receptor 1)RET (Rearranged during transfection receptor tyrosine kinase)
Beyond the preview
Go deeper on FOLFIRI + regorafenib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on FOLFIRI + regorafenib.